CN Patent

CN105008357A — 选择性cdk4/6抑制剂的固态形式

Assigned to Pfizer Inc · Expires 2015-10-28 · 11y expired

What this patent protects

本发明涉及具有改善的性质的式(<u>1</u>)乙酰基-8-环戊基-5-甲基-2-(5-哌嗪-1-基-吡啶-2-基氨基)-8H-吡啶并[2,3-d]嘧啶-7-酮的结晶游离碱、包含该游离碱的药物组合物及剂型、以及制备及使用所述化合物、组合物及剂型用于治疗细胞增生疾病(诸如癌症)的方法。

USPTO Abstract

本发明涉及具有改善的性质的式(<u>1</u>)乙酰基-8-环戊基-5-甲基-2-(5-哌嗪-1-基-吡啶-2-基氨基)-8H-吡啶并[2,3-d]嘧啶-7-酮的结晶游离碱、包含该游离碱的药物组合物及剂型、以及制备及使用所述化合物、组合物及剂型用于治疗细胞增生疾病(诸如癌症)的方法。

Drugs covered by this patent

Patent Metadata

Patent number
CN105008357A
Jurisdiction
CN
Classification
—
Expires
2015-10-28
Drug substance claim
No
Drug product claim
No
Assignee
Pfizer Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.